Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H25N3O |
Molar mass | 347.462 g·mol−1 |
3D model (JSmol) | |
| |
|
CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug,[1] first being identified in Germany in February 2020.[2] It is illegal in Finland.[3]